1 / 1

30-Day Mortality Rate Comparison: Dabigatran vs Warfarin After Major Bleeding Events

This analysis discusses the 30-day mortality rates following major bleeding events in patients from five Phase III trials comparing dabigatran and warfarin. The adjusted odds ratio for mortality indicates a trend favoring dabigatran with an odds ratio of 0.66 (95% CI: 0.44-1.00, P=0.051). The findings suggest that while dabigatran shows a potential reduction in mortality post-major bleeding compared to warfarin, the results warrant further investigation due to the borderline statistical significance.

lumina
Télécharger la présentation

30-Day Mortality Rate Comparison: Dabigatran vs Warfarin After Major Bleeding Events

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 0.2 - 30-day mortalityrateafter a major bleedingevent, in 5 phase III trials comparing dabigatran with warfarin Adjusted OR: 0.66 (95%CI: 0.44-1.00, P=0.051) 0.1 Mortalityrate (%) Warfarin Dabigatran 0.0 0 5 10 15 20 25 30 35 Time (days) Majeedet al.,Circulation 2013

More Related